Topic: Lantus
PARIS (Reuters) - French drugmaker Sanofi said a late-stage study of its lixisenatide drug in combination with Lantus insulin showed a significant improvement in blood sugar levels and a beneficial effect on body weight in type 2 diabetes patients.Lixisenatide, which will be ...
SAN DIEGO (Reuters) - Obesity and longevity have helped make diabetes an epidemic in much of the world, and drugmakers are jockeying to make sure their medicines are used early and often.Companies including Sanofi and Eli Lilly aim to introduce new classes ...
Danish pharmaceutical company Novo Nordisk said Thursday it planned to put a new insulin product on the market by 2013 after tests showed advantages to the widely sold diabetes drug Lantus."We believe that this ultra long-acting fourth-generation insulin will be a serious ...
Insulin glargine , marketed by Sanofi-Aventis under the name Lantus , is a long-acting basal insulin analogue , given once daily to help control the blood sugar level of those with diabetes . ?[2] European Medicines Agency update on safety of insulin ...
Lantus is an basal type of insulin that diabetics inject in order to have insulin in the background all of the time. People that have type 1 diabetes must always have some type of a basal insulin since they don't make any ...
Having Kids With Type 1 Diabetes So now we have two kids with Diabetes, two kits, two sets of insulin, meters, syringes, test strips, ect. Both my kids are on Lantus (long acting insulin) and Humalog (short acting). For example, at lunch, ...
Would you like to save money on your next prescription of Lantus insulin products? This Lantus coupons page will help you to save money on your prescriptions of this insulin medication for diabetics with type 1 or type 2 diabetes. You will ...
Last week, Sanofi-Aventis (SNY) confirmed that it is on the prowl for diabetes partnerships. may consider candidates for a successor to its best-selling product, the long-acting insulin Lantus, and for a new, fast-acting insulin. Herein lies the problem: diabetics trying to time ...
I am Lars Rebien S?rensen, the CEO of Novo Nordisk and with me I have our Chief Financial Officer, Jesper Brandgaard; Mads Krogsgaard Thomsen our Chief Science Officer; and several Investor Relations officers.. Sales growth in the first six months was 14% ...
SNY) announced today results of a study which demonstrated that patients using Lantus? (insulin glargine [rDNA origin] injection) once-daily and Apidra? (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin. People ...
